Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, published by Taylor & Francis Ltd, is a premier open-access journal that has been at the forefront of research in the field of medicinal chemistry since its inception in 1985. With an ISSN of 1475-6366 and an E-ISSN of 1475-6374, this journal boasts a prestigious reputation reflected in its impressive Q1 rankings across critical categories such as Drug Discovery and Pharmacology as of 2023. Situated in the United Kingdom, it plays a vital role in disseminating high-quality research that addresses the burgeoning needs of drug discovery and enzyme inhibition methodologies. The journal supports full open access, providing a platform for researchers, professionals, and students to share significant findings and innovations widely. With a robust impact factor, the JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY is indispensable for any academic or professional involved in the pharmacological sciences, offering an unparalleled insight into the latest advancements in therapeutic strategies and drug development.

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

European Journal of Medicinal Chemistry Reports, published by ELSEVIER, is a vital platform dedicated to advancing the field of medicinal chemistry through open access communication of high-quality research. With an impact factor reflecting its growing influence, this journal has rapidly established a reputation for scholarly excellence since its launch in 2021. It serves as a converging point for innovative studies and reviews that span the disciplines of chemistry and molecular medicine, reflected in its Q2 and Q3 quartile rankings in relevant categories for 2023. Situated in France, the journal is accessible globally, ensuring that researchers, professionals, and students can easily engage with significant findings and methodologies in medicinal chemistry. The open access model facilitates the dissemination of knowledge, bridging gaps between laboratory research and practical applications in drug development. By fostering collaboration and highlighting emerging trends, the European Journal of Medicinal Chemistry Reports plays a crucial role in shaping the future of therapeutic innovations.

Records of Natural Products is a distinguished journal focused on the dynamic fields of Drug Discovery, Organic Chemistry, Pharmacology, and Plant Science. Published by ACG PUBLICATIONS in Turkey, this journal serves as a vital platform for disseminating innovative research findings and advancements in natural product studies. With its convergence spanning from 2009 to 2024, Records of Natural Products holds a commendable position in the academic realm, featuring a 2023 Q3 ranking in Drug Discovery and Organic Chemistry, alongside a notable Q2 ranking in Plant Science. Despite its current lack of open access, the journal is committed to providing quality content that enriches the understanding of natural products and their potential applications. Researchers and professionals alike can benefit from the journal's insights, which not only contribute to scientific knowledge but also facilitate advancements in pharmaceuticals and sustainable practices. By exploring the rich tapestry of natural product research, this journal underscores its importance as a leading resource for professionals dedicated to enhancing the efficacy and application of natural compounds.

Journal of Natural Medicines, published by SPRINGER JAPAN KK, is a leading academic journal that plays a pivotal role in the advancement of research in the fields of Complementary and Alternative Medicine, Drug Discovery, Molecular Medicine, Organic Chemistry, and Pharmaceutical Science. Established in 1994 and set to continue until 2024, this journal serves as a vital conduit for the dissemination of groundbreaking research and innovative ideas that bridge traditional medicinal knowledge and modern scientific inquiry. With its impressive ranking in Scopus—ranking #12 out of 105 in Complementary and Alternative Medicine and holding a Q1 category quartile for 2023—it stands as a reputable source for high-quality, peer-reviewed articles. The journal's commitment to excellence is further underscored by its inclusion in the Springer network, providing researchers, professionals, and students with valuable insights and the latest developments in natural medicines. Although this journal operates under a subscription model, its profound impact on these interdisciplinary fields makes it an essential resource for anyone engaged in the study or practice of natural medicinal therapies.

Open Chemistry, published by DE GRUYTER POLAND SP Z O O, is a distinguished peer-reviewed journal that has been serving the global chemistry community since its inception. With an ISSN of 2391-5420 and an E-ISSN also of 2391-5420, this open-access journal has been accessible to researchers and practitioners alike since 2015, ensuring a wide dissemination of high-quality research findings. Located in Germany, specifically at BOGUMILA ZUGA 32A STR, 01-811 WARSAW, MAZOVIA, POLAND, Open Chemistry aims to publish innovative research across various chemical disciplines, with special attention to miscellaneous chemistry and materials chemistry. It is currently ranked in the Q3 category for both fields as of 2023, reflecting its solid standing within the academic community, with specific ranks of 187/408 in General Chemistry and 153/317 in Materials Chemistry, corresponding to respective percentiles of 54 and 51. Open Chemistry not only enhances the accessibility of cutting-edge research but also serves as a vital resource for students, professionals, and scholars seeking to advance their knowledge in the rapidly evolving landscape of chemical sciences.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.